



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

April 5, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – April 3, 2021

TOTAL Cases Reported Since 1/22/20

30,492,334

NEW Cases Reported to CDC on 4/3/21

67,989

Change in 7-Day Case Average

+6.5%


Current 7-Day Case Average (3/28/21 - 4/3/21)

64,001

Prior 7-Day Case Average (3/21/21 - 3/27/21)

60,085

Peaks in New Cases and Highest 7-Day Moving Average		
	Highest Daily Number of New Cases	Highest 7-Day Moving Average
Current	315,163 (1/8/21)	250,446 (1/11/21)
2nd Peak	75,319 (7/17/20)	67,337 (7/23/20)
1st Peak	42,568 (4/6/20)	31,915 (4/12/20)



*7-day averages exclude historical cases reported retroactively by states



New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – April 2, 2021

Patients Currently Hospitalized with COVID on 4/2/21

32,105

New Admissions on 4/2/21

4,914

Peak in New Admissions (1/5/21)

17,988

Change in 7-Day Average of New Admissions


+2.6%

Current 7-Day Average of New Admissions (3/27/21 - 4/2/21)

4,971

Prior 7-Day Average of New Admissions (3/20/21 - 3/26/21)

4,844



Daily Change in COVID-19 Deaths, United States

January 22, 2020 – April 3, 2021

TOTAL Deaths Reported Since 1/22/2020

553,681

NEW Deaths Reported to CDC on 4/3/21

789

Change in 7-Day Death Average

-16.9%

Current 7-Day Death Average (3/28/21 - 4/3/21)


804

Prior 7-Day Death Average (3/21/21 - 3/27/21)

968


Forecasted Total Deaths by 4/24/21

565,000 to 585,000





WEAR A MASK



STAY 6 FEET APART




AVOID CROWDS



AVOID TRAVEL

**COVID-19 in Pregnancy is
Associated with Adverse
Outcomes for Mother and Baby**



The Importance of Vaccination





Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020

- Analysis of ~400,000 women aged 15–44 years with symptomatic COVID-19
- Though absolute numbers are small, increased risk among pregnant women (versus non-pregnant women) for

	<u>Adjusted risk ratio (RR)</u>
– Intensive care unit admission	3.0
– Invasive ventilation	2.9
– Extracorporeal membrane oxygenation	2.4
– Death	1.5

March 19, 2021

cmaJ

The Impact of COVID-19 on Pregnancy Outcomes: A Systematic Review and Meta-Analysis

SQ Wei, N Auger et al.

- 42 studies involving 438,548 pregnant women
- Compared with no SARS-CoV-2 infection in pregnancy, COVID-19 associated with increased
 - Preeclampsia (OR 1.33)
 - Preterm birth (OR 1.82)
 - Stillbirth (OR 2.11)
- Compared with mild COVID-19, severe COVID-19 strongly associated with
 - Preeclampsia (OR 4.16)
 - Preterm birth (OR 4.29)
 - Gestational diabetes (OR 1.99)
 - Low birth weight (OR 1.89)



COVID-19 Vaccines in Pregnancy: Limited Data, but No Safety Concerns to Date

- **Use of adenovirus-based vaccines for other diseases not associated with adverse pregnancy-related outcomes**
- **Pregnant women not included in COVID-19 vaccine clinical trials; however, observational data from vaccinated pregnant individuals are being collected by CDC and manufacturers**
- **Based on self-reported information, no specific safety signals have been observed among pregnant vaccine recipients included in the CDC v-safe registry**





ACOG

The American College of
Obstetricians and Gynecologists

February 3, 2021

News Release

Maternal Immunization Task Force and Partners Urge That COVID-19 Vaccine be Available to Pregnant Individuals

- **All pregnant individuals who choose to receive the COVID-19 vaccine must be allowed to do so in alignment with their state and local vaccination allocation plan**



V-safe COVID-19 Vaccine Pregnancy Registry

- **As of March 29, 2021, 69,337 v-safe participants have indicated they were pregnant at the time they received COVID-19 vaccination**
- **CDC is currently enrolling eligible participants and analyzing data to better understand how COVID-19 vaccination affects pregnant people**

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafepregnancyregistry.html>



COVID-19 Vaccine Response in Pregnant and Lactating Women: A Cohort Study

KJ Gray, AG Edlow et al.

- 131 reproductive-age vaccine recipients (84 pregnant, 31 lactating, and 16 non-pregnant) were enrolled in a prospective cohort study at two academic medical centers
- COVID-19 mRNA vaccines generated robust humoral immunity in pregnant and lactating women, with immunogenicity and reactogenicity similar to that observed in non-pregnant women
- Vaccine-induced immune responses were significantly greater than the response to natural infection
- Immune transfer to neonates occurred via placenta and breastmilk



THE WHITE HOUSE
WASHINGTON

WH.GOV